Is Gvoke Approved for Children Under 2?
No, Gvoke (glucagon injection) is not approved for use in children under 2 years old. The FDA labeling specifies safety and effectiveness only in patients aged 2 years and older.[1] Gvoke is indicated for severe hypoglycemia in patients with diabetes, but pediatric data below age 2 is lacking, and it's not recommended due to insufficient clinical studies.
What Happens If Used Off-Label in Infants?
Off-label use in children under 2 is not advised without medical supervision, as glucagon's effects—like rapid blood sugar rise—can cause vomiting or aspiration risks in very young patients. Limited case reports exist for neonatal hypoglycemia, but no formal trials support routine use. Consult a pediatric endocrinologist for alternatives.[1][2]
What Are the Approved Age Limits and Dosing?
Gvoke HypoPen and Syringe are approved for ages 2 and up:
- Ages 2-15 years (or <25 kg): 0.5 mg dose.
- Adults and patients ≥25 kg: 1 mg dose.
Administration is intramuscular or subcutaneous, with onset in 10-15 minutes.[1]
Alternatives for Hypoglycemia in Kids Under 2?
For infants and toddlers under 2:
- Glucagon alternatives: Standard glucagon kits (e.g., Glucagon Emergency Kit) may be used off-label in emergencies, but data is sparse. Baqsimi (nasal glucagon) is approved only for ages 4+.[3]
- First-line treatments: Fast-acting carbs like glucose gel or juice for conscious kids; IV dextrose in hospitals.
- Emerging options: Dasiglucagon (Zegalogue) is approved for ages 6 months and older at 0.6 mg subcutaneous dose, offering a closer alternative for this group.[4]
Why the Age Restriction on Gvoke?
The restriction stems from pediatric exclusivity rules and trial exclusions. Gvoke's approval relied on adult and older pediatric data; trials didn't enroll under-2s due to ethical concerns over hypoglycemia induction. No pediatric patent extensions cover this gap.[1][5]
[1]: Gvoke Prescribing Information (FDA)
[2]: American Diabetes Association Standards of Care 2023
[3]: Baqsimi Prescribing Information (FDA)
[4]: Zegalogue Prescribing Information (FDA)
[5]: DrugPatentWatch.com - Gvoke Patents